Bezuclastinib

Name: Bezuclastinib in Gastrointestinal stromal tumor: Clinical presentation - signs and symptoms
Published: 2026-09-14T15:39:06-04:00

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Clinical presentation - signs and symptoms

3 evidence topics · 1 source

Bleeding and anemia

“GI bleeding (most common presentation), which may be acute (melena or hematemesis) or chronic, resulting in anemia.” (opens the source at this quote in a new tab)

Obstruction, swallowing difficulty, and early satiety

“GI obstruction.” (opens the source at this quote in a new tab)
“Dysphagia.” (opens the source at this quote in a new tab)
“Early satiety.” (opens the source at this quote in a new tab)

Pain

“Pain.” (opens the source at this quote in a new tab)